Product Data Sheet

GPP78

Cat. No.: HY-14374 CAS No.: 1202580-59-3 Molecular Formula: $C_{27}H_{29}N_{5}O$ Molecular Weight: 439.55

Target: NAMPT; Autophagy

Pathway: Metabolic Enzyme/Protease; Autophagy

Solution, -20°C, 2 years Storage:

BIOLOGICAL ACTIVITY

Description GPP78 (CAY10618) is a potent Nampt inhibitor with an IC₅₀ of 3.0 nM for nicotinamide adenine dinucleotide (NAD) depletion. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC₅₀ of 3.8 nM by inducing autophagy. GPP78 has anti-

cancer and anti-inflammatory effects^{[1][2]}.

IC₅₀ & Target Nampt^[1];

Autophagy^[1]

In Vitro

GPP78 (Compound 8; 10 nM; 24-40 hours; SH-SY5Y cells) treatment with cells, punctate staining of LC3-II and the formation of autophagolysosomes are observable. LC3-II is membrane-bound and is present in autophagosomes [1]. GPP78 (Compound 8) inhibits the growth of most cell lines tested, with nanomolar potency (GI₅₀) in cell lines derived from

leukemia, lung, CNS, colon, melanoma, ovarian, renal, and prostate cancers. GPP78 appears truly cytotoxic in melanoma cell lines, while in the others it is mainly cytostatic [1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	SH-SY5Y cells
Concentration:	10 nM
Incubation Time:	24 hours, 40 hours
Result:	Punctate staining of LC3-II and the formation of autophagolysosomes were observable.

In Vivo

GPP78 (10 mg/kg; intraperitoneal injection; daily; 1 hour or 6 hours after SCI; for 19 days; male adult CD1 mice) treatment reduces the severity of spinal cord trauma in SCI mice[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male adult CD1 mice (25-30 g) with spinal cord injury (SCI) ^[2]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; daily; 1 hour or 6 hours after SCI; for 19 days

d with SCI. And significantly ameliorated	Result:

CUSTOMER VALIDATION

• Sci Signal. 2021 Jun 8;14(686):eabc7405.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. Colombano G, et al. A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J Med Chem. 2010 Jan 28;53(2):616-23.

[2]. Esposito E, et al. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. J Neuroinflammation. 2012 Apr 10;9:66.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech @ Med Chem Express.com$

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA